244 related articles for article (PubMed ID: 7676459)
1. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalyzed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000g supernatant.
Liu L; Wells PG
Toxicol Appl Pharmacol; 1995 Sep; 134(1):71-80. PubMed ID: 7676459
[TBL] [Abstract][Full Text] [Related]
2. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets of chemical teratogenesis.
Liu L; Wells PG
Toxicol Appl Pharmacol; 1994 Apr; 125(2):247-55. PubMed ID: 8171432
[TBL] [Abstract][Full Text] [Related]
3. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice.
Yu WK; Wells PG
Toxicol Appl Pharmacol; 1995 Mar; 131(1):1-12. PubMed ID: 7878664
[TBL] [Abstract][Full Text] [Related]
4. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues.
Liu L; Wells PG
Free Radic Biol Med; 1995 Nov; 19(5):639-48. PubMed ID: 8529923
[TBL] [Abstract][Full Text] [Related]
5. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture.
Miranda AF; Wiley MJ; Wells PG
Toxicol Appl Pharmacol; 1994 Feb; 124(2):230-41. PubMed ID: 8122268
[TBL] [Abstract][Full Text] [Related]
6. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity.
Winn LM; Wells PG
Mol Pharmacol; 1995 Jul; 48(1):112-20. PubMed ID: 7623765
[TBL] [Abstract][Full Text] [Related]
7. Oxidative damage in chemical teratogenesis.
Wells PG; Kim PM; Laposa RR; Nicol CJ; Parman T; Winn LM
Mutat Res; 1997 Dec; 396(1-2):65-78. PubMed ID: 9434860
[TBL] [Abstract][Full Text] [Related]
8. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis.
Winn LM; Wells PG
Free Radic Biol Med; 1997; 22(4):607-21. PubMed ID: 9013124
[TBL] [Abstract][Full Text] [Related]
9. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.
Parman T; Wiley MJ; Wells PG
Nat Med; 1999 May; 5(5):582-5. PubMed ID: 10229238
[TBL] [Abstract][Full Text] [Related]
10. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthetase, horseradish peroxidase, and thyroid peroxidase.
Kubow S; Wells PG
Mol Pharmacol; 1989 Apr; 35(4):504-11. PubMed ID: 2539558
[TBL] [Abstract][Full Text] [Related]
11. Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice.
Ozolins TR; Siksay DL; Wells PG
J Pharmacol Exp Ther; 1996 May; 277(2):945-53. PubMed ID: 8627577
[TBL] [Abstract][Full Text] [Related]
12. Phenytoin-initiated hydroxyl radical formation: characterization by enhanced salicylate hydroxylation.
Kim PM; Wells PG
Mol Pharmacol; 1996 Jan; 49(1):172-81. PubMed ID: 8569704
[TBL] [Abstract][Full Text] [Related]
13. Biochemical toxicology of chemical teratogenesis.
Wells PG; Winn LM
Crit Rev Biochem Mol Biol; 1996 Feb; 31(1):1-40. PubMed ID: 8744954
[TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species.
Wells PG; Bhuller Y; Chen CS; Jeng W; Kasapinovic S; Kennedy JC; Kim PM; Laposa RR; McCallum GP; Nicol CJ; Parman T; Wiley MJ; Wong AW
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):354-66. PubMed ID: 16081118
[TBL] [Abstract][Full Text] [Related]
16. The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase knockout mice.
Kasapinovic S; McCallum GP; Wiley MJ; Wells PG
Free Radic Biol Med; 2004 Dec; 37(11):1703-11. PubMed ID: 15528029
[TBL] [Abstract][Full Text] [Related]
17. Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes.
Roy D; Snodgrass WR
J Pharmacol Exp Ther; 1990 Mar; 252(3):895-900. PubMed ID: 2319474
[TBL] [Abstract][Full Text] [Related]
18. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
Kim PM; Winn LM; Parman T; Wells PG
J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197
[TBL] [Abstract][Full Text] [Related]
19. Phenytoin embryotoxicity: role of enzymatic bioactivation in a murine embryo culture model.
Shanks MJ; Wiley MJ; Kubow S; Wells PG
Teratology; 1989 Oct; 40(4):311-20. PubMed ID: 2814893
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of phenytoin in teratogenesis-susceptible and -resistant strains of mice.
Hansen DK; Hodes ME
Drug Metab Dispos; 1983; 11(1):21-4. PubMed ID: 6132790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
